Copyright
©The Author(s) 2018.
World J Gastroenterol. Oct 14, 2018; 24(38): 4384-4392
Published online Oct 14, 2018. doi: 10.3748/wjg.v24.i38.4384
Published online Oct 14, 2018. doi: 10.3748/wjg.v24.i38.4384
Parameter | n |
Age, yr, median (IQR) | 41 (28-52) |
Man/female | 67/64 |
Disease duration, yr, median (IQR) | 3.6 (2.0-10.1) |
Actual disease extent | |
Proctitis | 29 (22.2) |
Left-sided colitis | 24 (18.3) |
Total colitis | 76 (58.0) |
Segmental colitis | 2 (1.5) |
Partial Mayo score | |
< 2 | 93 (71.0) |
2-4 | 28 (21.4) |
5-7 | 8 (6.1) |
> 7 | 2 (1.5) |
Laboratory data | |
WBC, /μL, median (IQR) | 6525 (4838-8140) |
CRP, mg/dL, median (IQR) | 0.1 (0.04-0.20) |
ESR, mm/h, median (IQR) | 7 (4-11) |
Albumin, g/dL, median (IQR) | 4.3 (4.0-4.6) |
Hemoglobin, g/dL, median (IQR) | 13.6 (12.1-14.3) |
Platelets, × 1000/μL, median (IQR) | 268 (190-320) |
FC, μg/g, median (IQR) | 289 (78-785) |
Medication | |
Mesalazine, oral | 112 (85.5) |
Mesalazine, topical | 12 (9.2) |
Immunomodulators | 47 (35.9) |
Anti-TNF | 21 (16.0) |
Corticosteroids | 17 (13.0) |
Parameter | Relapsed patients (n = 19) | Non-relapsed patients (n = 69) | P value |
Age, yr, median (IQR) | 35 (23-53) | 40 (29-52) | 0.26 |
Male/female | 6/13 | 37/32 | 0.08 |
Actual disease extent | |||
Proctitis | 5 (26.3) | 18 (26.1) | 0.53 |
Left-sided colitis | 1 (5.3) | 12 (17.4) | |
Total colitis | 13 (68.4) | 38 (55.1) | |
Segmental colitis | 0 (0) | 1 (1.4) | |
Laboratory data | |||
WBC, /μL, median (IQR) | 6130 (5110-7745) | 5585 (4640-7013) | 0.48 |
CRP, mg/dL, median (IQR) | 0.05 (0.01-0.10) | 0.1 (0.04-0.14) | 0.05 |
ESR, mm/h, median (IQR) | 6 (4-8) | 5 (3.0-10.0) | 0.69 |
Albumin, g/dL, median (IQR) | 4.4 (4.3-4.6) | 4.4 (4.1-4.6) | 0.75 |
Hemoglobin, g/dL, median (IQR) | 13.3 (12.3-14.4) | 13.9 (12.6-14.9) | 0.25 |
Platelets, × 1000/μL, median (IQR) | 238 (214-339) | 256 (213-294) | 0.92 |
FC, μg/g, median (IQR) | 303 (94-846) | 126 (55.5-485) | 0.05 |
Medication | |||
Mesalazine, oral | 14 (73.7) | 64 (92.8) | 0.03 |
Mesalazine, topical | 1 (5.3) | 3 (4.3) | 0.87 |
Immunomodulators | 6 (31.6) | 18 (26.1) | 0.98 |
Anti-TNF | 4 (21.1) | 12 (17.4) | 0.71 |
Corticosteroids | 3 (15.8) | 5 (7.2) | 0.28 |
Variable | Cut-off value (μg/g) | AUC | 95%CI | Sensitivity (%) | Specificity(%) | PPV (%) | PLR | Accuracy (%) |
Relapse | 175 | 0.648 | 0.517-0.778 | 68 | 61 | 33 | 1.75 | 63 |
PMS 0 | 289 | 0.796 | 0.714-0.878 | 72 | 84 | 88 | 4.48 | 76 |
MES 0 | 490 | 0.823 | 0.707-0.939 | 100 | 62 | 42 | 2.6 | 70 |
REI 0 | 288 | 0.78 | 0.658-0.903 | 100 | 70 | 32 | 3.38 | 74 |
UCEIS 0 | 288 | 0.777 | 0.645-0.909 | 88 | 71 | 37 | 3.06 | 74 |
Riley’s score 0 | 125 | 0.881 | 0.780-0.981 | 80 | 86 | 62 | 5.76 | 85 |
Matts grade 1 | 123 | 0.918 | 0.831-1.000 | 88 | 87 | 58 | 6.65 | 87 |
- Citation: Urushikubo J, Yanai S, Nakamura S, Kawasaki K, Akasaka R, Sato K, Toya Y, Asakura K, Gonai T, Sugai T, Matsumoto T. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis. World J Gastroenterol 2018; 24(38): 4384-4392
- URL: https://www.wjgnet.com/1007-9327/full/v24/i38/4384.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i38.4384